Evidence map›Paper›PMID 33467597›Full record

ReviewBiomolecules2021

Breakdown of Filamentous Myofibrils by the UPS-Step by Step.

Dina Aweida, Shenhav Cohen

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Maximum entropy determination of mammalian proteome dynamics.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  7. βFrontiers in physiology · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Dina AweidaFaculty of Biology, Technion Institute of Technology, Haifa 32000, Israel.
Shenhav CohenFaculty of Biology, Technion Institute of Technology, Haifa 32000, Israel.ORCID 0000-0001-8307-466X
Technion – Israel Institute of Technology · IL

Funding

Israel Ministry of Science, Technology and Space 2015-3-74Israel Science Foundation 1068/19Israel Science Foundation 623/15
6 · The paper itself

Abstract

Protein degradation maintains cellular integrity by regulating virtually all biological processes, whereas impaired proteolysis perturbs protein quality control, and often leads to human disease. Two major proteolytic systems are responsible for protein breakdown in all cells: autophagy, which facilitates the loss of organelles, protein aggregates, and cell surface proteins; and the ubiquitin-proteasome system (UPS), which promotes degradation of mainly soluble proteins. Recent findings indicate that more complex protein structures, such as filamentous assemblies, which are not accessible to the catalytic core of the proteasome in vitro, can be efficiently degraded by this proteolytic machinery in systemic catabolic states in vivo. Mechanisms that loosen the filamentous structure seem to be activated first, hence increasing the accessibility of protein constituents to the UPS. In this review, we will discuss the mechanisms underlying the disassembly and loss of the intricate insoluble filamentous myofibrils, which are responsible for muscle contraction, and whose degradation by the UPS causes weakness and disability in aging and disease. Several lines of evidence indicate that myofibril breakdown occurs in a strictly ordered and controlled manner, and the function of AAA-ATPases is crucial for their disassembly and loss.

Indexed as

AnimalsHumansMuscle ProteinsMyofibrilsProteasome Endopeptidase ComplexUbiquitinUbiquitinationUbiquitin-Protein LigasesMuscle ProteinsProteasome Endopeptidase ComplexUbiquitinUbiquitin-Protein LigasesAAA-ATPasesautophagyintermediate filamentsmuscle atrophymyofibrilsproteasomeubiquitin

Identifiers

PMID33467597
PMCPMC7830001
OpenAlexW3118600681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.